tetano
Editor, Senior Moderator
Allergy Asthma Clin Immunol
. 2022 Aug 25;18(1):78.
doi: 10.1186/s13223-022-00719-6.
Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients
Takeo Nakajima[SUP] 1 [/SUP], Tatsuya Nagano[SUP] 2 [/SUP], Yoshiharu Miyata[SUP] 3 [/SUP], Shoko Murakami[SUP] 4 [/SUP], Satoshi Mitsuyuki[SUP] 5 [/SUP], Yohei Funakoshi[SUP] 6 [/SUP], Kimikazu Yakushijin[SUP] 6 [/SUP], Hitoshi Horimoto[SUP] 7 [/SUP], Yoshihiro Nishimura[SUP] 8 [/SUP], Kazuyuki Kobayashi[SUP] 4 [/SUP]
Affiliations
Abstract
Objectives: Oral corticosteroids reduce the antibody titer of the BNT162b2 mRNA vaccine against SARS-CoV-2. To date, the effect of inhaled corticosteroids on antibody titers is unknown.
Study design: The design of this study is retrospective study.
Methods: We analyzed the relationship between the clinical features and total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in 320 subjects who had never been infected with Coronavirus disease 2019 (COVID-19) and were vaccinated the second time with the BNT162b2 mRNA vaccine between October 1 to December 28, 2021.
Results: Of the 320 subjects, 205 were treated with inhaled corticosteroids. The median antibody titer of patients treated with inhaled corticosteroids was 572 U/mL, which was significantly higher than that of patients treated without inhaled corticosteroids (454U/mL, P = 0.00258). The median antibody titers of smokers, men, and patients aged 65 years and over, were 315.5 U/mL, 385 U/mL, and 425.5 U/mL, respectively. These results are significantly lower than those of patients who never smoked, women, and patients aged less than 64 years (582 U/mL [P < 0.0001], 682.5 U/mL [P < 0.0001], and 717 U/mL [P < 0.0001], respectively). The multivariate analysis revealed that females and age were independent antibody titer-reducing factors (P = 0.0001 and P < 0.0001, respectively).
Conclusions: The use of inhaled corticosteroids did not reduce the antibody titer against SARS-CoV-2 spike protein. Clinicians should continue treatment with inhaled corticosteroids if indicated.
Keywords: Asthma; BNT162b2 mRNA vaccine; Inhaled corticosteroid; SARS-CoV-2.
. 2022 Aug 25;18(1):78.
doi: 10.1186/s13223-022-00719-6.
Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients
Takeo Nakajima[SUP] 1 [/SUP], Tatsuya Nagano[SUP] 2 [/SUP], Yoshiharu Miyata[SUP] 3 [/SUP], Shoko Murakami[SUP] 4 [/SUP], Satoshi Mitsuyuki[SUP] 5 [/SUP], Yohei Funakoshi[SUP] 6 [/SUP], Kimikazu Yakushijin[SUP] 6 [/SUP], Hitoshi Horimoto[SUP] 7 [/SUP], Yoshihiro Nishimura[SUP] 8 [/SUP], Kazuyuki Kobayashi[SUP] 4 [/SUP]
Affiliations
- PMID: 36008820
- DOI: 10.1186/s13223-022-00719-6
Abstract
Objectives: Oral corticosteroids reduce the antibody titer of the BNT162b2 mRNA vaccine against SARS-CoV-2. To date, the effect of inhaled corticosteroids on antibody titers is unknown.
Study design: The design of this study is retrospective study.
Methods: We analyzed the relationship between the clinical features and total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in 320 subjects who had never been infected with Coronavirus disease 2019 (COVID-19) and were vaccinated the second time with the BNT162b2 mRNA vaccine between October 1 to December 28, 2021.
Results: Of the 320 subjects, 205 were treated with inhaled corticosteroids. The median antibody titer of patients treated with inhaled corticosteroids was 572 U/mL, which was significantly higher than that of patients treated without inhaled corticosteroids (454U/mL, P = 0.00258). The median antibody titers of smokers, men, and patients aged 65 years and over, were 315.5 U/mL, 385 U/mL, and 425.5 U/mL, respectively. These results are significantly lower than those of patients who never smoked, women, and patients aged less than 64 years (582 U/mL [P < 0.0001], 682.5 U/mL [P < 0.0001], and 717 U/mL [P < 0.0001], respectively). The multivariate analysis revealed that females and age were independent antibody titer-reducing factors (P = 0.0001 and P < 0.0001, respectively).
Conclusions: The use of inhaled corticosteroids did not reduce the antibody titer against SARS-CoV-2 spike protein. Clinicians should continue treatment with inhaled corticosteroids if indicated.
Keywords: Asthma; BNT162b2 mRNA vaccine; Inhaled corticosteroid; SARS-CoV-2.